These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 38311667)

  • 1. Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment.
    Wulff AB; Nordestgaard BG; Langsted A
    Curr Atheroscler Rep; 2024 Apr; 26(4):111-118. PubMed ID: 38311667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy.
    Langsted A; Nordestgaard BG
    Curr Atheroscler Rep; 2021 Jun; 23(8):46. PubMed ID: 34148150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.
    Boffa MB
    Curr Atheroscler Rep; 2016 Dec; 18(12):69. PubMed ID: 27761705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus Seminar 2/3.
    Malick WA; Goonewardena SN; Koenig W; Rosenson RS
    J Am Coll Cardiol; 2023 Apr; 81(16):1633-1645. PubMed ID: 37076218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations for routinely testing for high Lp(a).
    Nurmohamed NS; Moriarty PM; Stroes ESG
    Curr Opin Lipidol; 2022 Jun; 33(3):213-218. PubMed ID: 35695619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein(a): cardiovascular risk and emerging therapies.
    Fujino M; Nicholls SJ
    Expert Rev Cardiovasc Ther; 2023 Apr; 21(4):259-268. PubMed ID: 37010028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lp(a): a New Pathway to Target?
    Nurmohamed NS; Kraaijenhof JM; Stroes ESG
    Curr Atheroscler Rep; 2022 Nov; 24(11):831-838. PubMed ID: 36066785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations for routinely testing for high lipoprotein(a).
    Nurmohamed NS; Moriarty PM; Stroes ES
    Curr Opin Lipidol; 2023 Aug; 34(4):174-179. PubMed ID: 35942815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent lipoprotein(a) trials.
    Wei T; Cho L
    Curr Opin Lipidol; 2022 Dec; 33(6):301-308. PubMed ID: 36345866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics.
    Tasdighi E; Adhikari R; Almaadawy O; Leucker TM; Blaha MJ
    Annu Rev Pharmacol Toxicol; 2024 Jan; 64():135-157. PubMed ID: 37506332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein(a): the revenant.
    Gencer B; Kronenberg F; Stroes ES; Mach F
    Eur Heart J; 2017 May; 38(20):1553-1560. PubMed ID: 28329241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lp(a): Addressing a Target for Cardiovascular Disease Prevention.
    Vasquez N; Joshi PH
    Curr Cardiol Rep; 2019 Jul; 21(9):102. PubMed ID: 31367887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics.
    Swerdlow DI; Rider DA; Yavari A; Wikström Lindholm M; Campion GV; Nissen SE
    Cardiovasc Res; 2022 Mar; 118(5):1218-1231. PubMed ID: 33769464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies.
    Alhomoud IS; Talasaz A; Mehta A; Kelly MS; Sisson EM; Bucheit JD; Brown R; Dixon DL
    Pharmacotherapy; 2023 Oct; 43(10):1051-1063. PubMed ID: 37464942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk.
    Tsimikas S
    Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):157-64. PubMed ID: 26825471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latest developments in the treatment of lipoprotein (a).
    Bos S; Yayha R; van Lennep JE
    Curr Opin Lipidol; 2014 Dec; 25(6):452-60. PubMed ID: 25318824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapy for children with elevated levels of lipoprotein(a): future directions.
    de Boer LM; Wiegman A; Swerdlow DI; Kastelein JJP; Hutten BA
    Expert Opin Pharmacother; 2022 Oct; 23(14):1601-1615. PubMed ID: 36047306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies.
    Chan DC; Watts GF
    Clin Ther; 2023 Nov; 45(11):1034-1046. PubMed ID: 37524569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 10 essential questions regarding lipoprotein(a).
    Kostner KM; Kostner GM
    Curr Opin Clin Nutr Metab Care; 2024 Mar; 27(2):136-143. PubMed ID: 37997792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein(a) and Cardiovascular Disease.
    Kamstrup PR
    Clin Chem; 2021 Jan; 67(1):154-166. PubMed ID: 33236085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.